Establishment of a Brain and Spinal Tumor Tissue Bank

Taipei Medical University WanFang Hospital70 enrolled

Overview

The purpose of this study is to establish a Brain and Spinal Tumor Tissue/Specimen repository to serve as a resource for current and future scientific studies.

Glioblastoma multiforme (GBM) is the most common and lethal primary Brain and Spinal Tumor in adults. It is nearly uniformly fatal, with a median survival of approximately one year, despite modern treatment modalities. Efforts to understand why some patients live longer or shorter than the average may provide insights into the biology of these neoplasms. For years, researchers have tried to identify independent predictors that could help in treatment planning. With the recent interest in molecular biology and molecular genetics, tumor markers are now being examined as potential predictors. A marker that could predict tumor response to therapy, the likelihood of recurrence, and survival would thus be quite useful.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Glioblastoma Multiforme Glioma Neuroectodermal Tumors

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have a suspected or confirmed diagnosis of Brain and Spinal Tumor * Age greater than 20 * Signed consent Exclusion Criteria: * Known HIV infection * Any other clinical condition which, in the opinion of the principal investigator, would not allow completion of this study

Locations (1)

Taipei Medical University-Wan Fang Hospital

Taipei, Taiwan

RECRUITING

Outcomes

Primary Outcomes

Collect, annotate, and store fresh frozen specimens of normal tissue, tumors, and pre-malignant lesions for biological investigation.

Time frame: 5 years

Secondary Outcomes

Collect, process, and store serum, plasma and isolate lymphocytes from blood drawn from patients with Brain and Spinal Tumor

Time frame: 5 years

Establish a database to link materials acquisition, pathologic, and clinical information on patients who participate in the protocol

Time frame: 5 years

To utilize the clinical database to perform clinical and pathological correlation with the results of current and future scientific studies

Time frame: 5 years

To evaluate various NAT2, EGFR and MGMT for evidence of genomic and biochemical activation

Time frame: 5 years

To test the effect of small molecule inhibitors on the activation of wild-type and mutant NAT2, EGFR, MGMT and/or other potential molecular targets

Time frame: 5 years

To correlate tumor genotype and signaling abnormalities with clinical response to NAT2, EGFR, MGMT and/or other potential molecular targets inhibitors

Time frame: 5 years

Analysis of laboratory findings in relationship to patient demographics and clinical course

Time frame: 5 years

Central Contacts

Kuo-Sheng Hung, M.D., Ph. D.

CONTACT

886-2-2930-7930 kshung25@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.